Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 12, Issue 1 (Vol.12 No.1 Apr 2023)
rbmb.net 2023, 12(1): 102-111 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Elhelaly Elsherbeny M, Ramadan Elsergany A, Gamil Shaker O. Association of lncRNA MEG3 Rs7158663 Polymorphism and Serum Expression with Colorectal Cancer in Egyptian Patients. rbmb.net 2023; 12 (1) :102-111
URL: http://rbmb.net/article-1-1111-en.html
URL: http://rbmb.net/article-1-1111-en.html
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Abstract: (1467 Views)
Background: Colorectal cancer (CRC) is considered the third most common cancer around the world and second in terms of mortality. A significant aspect in its development is genetics. The risk of CRC and other clinicopathologic characteristics were investigated in this work in relation to the long non-coding RNA (lncRNA) MEG3 rs7158663 polymorphism, MEG3 expression, in an Egyptian population.
Methods: 160 CRC patients and 160 healthy controls were enrolled in this case-control study. The lncRNA MEG3 rs7158663 was examined using TaqMan Real-time PCR. RT-PCR was used to assess the levels of serum MEG3 expression.
Results: A significant higher expression of ‘A’ allele (risk allele) and A/A genotype in CRC cases vs. control subjects (P <0.001) Participants with A/A genotype had 4.8 times higher odds to exhibit CRC. Serum MEG3 gene expression was generally low in CRC patients, and it was considerably lower in those with the rs7158663 AA genotype than those with the GG genotype (P <0.001). It was found that CRC patients with the rs7158663 GA genotype had lower serum MEG3 expression levels than those with the GG genotype (P <0.001).
Conclusions: MEG3 low expression and MEG3 rs7158663 (AA) were associated with CRC risk in Egyptian patients and may serve as a diagnostic and prognostic marker for CRC patients.
Methods: 160 CRC patients and 160 healthy controls were enrolled in this case-control study. The lncRNA MEG3 rs7158663 was examined using TaqMan Real-time PCR. RT-PCR was used to assess the levels of serum MEG3 expression.
Results: A significant higher expression of ‘A’ allele (risk allele) and A/A genotype in CRC cases vs. control subjects (P <0.001) Participants with A/A genotype had 4.8 times higher odds to exhibit CRC. Serum MEG3 gene expression was generally low in CRC patients, and it was considerably lower in those with the rs7158663 AA genotype than those with the GG genotype (P <0.001). It was found that CRC patients with the rs7158663 GA genotype had lower serum MEG3 expression levels than those with the GG genotype (P <0.001).
Conclusions: MEG3 low expression and MEG3 rs7158663 (AA) were associated with CRC risk in Egyptian patients and may serve as a diagnostic and prognostic marker for CRC patients.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2022/12/13 | Accepted: 2023/02/16 | Published: 2023/08/15
Received: 2022/12/13 | Accepted: 2023/02/16 | Published: 2023/08/15
References
1. International Agency for Research on Cancer. Cancer Fact Sheets. Available from: http://gco.iarc.fr/today/fact-sheets-cancers.
2. Brand Bateman L, Khamess S, Abdelmoneim SE, Arafat W, Fouad MN, Khamis Y, et al. Designing an Effective Colorectal Cancer Screening Program in Egypt: A Qualitative Study of Perceptions of Egyptian Primary Care Physicians and Specialists. Oncologist. 2020;25(10):e1525-e1531. [DOI:10.1634/theoncologist.2019-0687] [PMID] [PMCID]
3. Shalmashi H, Safaei S, Shanehbandi D, Asadi M, Bornehdeli S, Mehdi Navaz A. Evaluation of lncRNA FOXD2-AS1 Expression as a Diagnostic Biomarker in Colorectal Cancer. Rep Biochem Mol Biol. 2022;11(3):471-478. [DOI:10.52547/rbmb.11.3.471] [PMID] [PMCID]
4. Bayatiani MR, Ahmadi A, Aghabozorgi R, Seif F. Concomitant Up-Regulation of Hsa- Mir-374 and Down-Regulation of Its Targets, GSK-3β and APC, in Tissue Samples of Colorectal Cancer. Rep Biochem Mol Biol. 2021;9(4):408-416. [DOI:10.52547/rbmb.9.4.408] [PMID] [PMCID]
5. Metwally IH, Shetiwy M, Elalfy AF, Abouzid A, Saleh SS, Hamdy M. Epidemiology and survival of colon cancer among Egyptians: a retrospective study. Journal of Coloproctology. 2018;38(10):24-9. [DOI:10.1016/j.jcol.2017.09.418]
6. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med. 2019;7(21):609. [DOI:10.21037/atm.2019.07.91] [PMID] [PMCID]
7. Elshafei A, Shaker O, Abd El-motaal O, Salman T. The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study. Tumour Biol. 2017;39(6):1010428317705765. [DOI:10.1177/1010428317705765] [PMID]
8. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev. 2003;12(8):755-62.
9. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403-8. [DOI:10.1002/ijc.10635] [PMID]
10. Mik M, Berut M, Dziki L, Trzcinski R, Dziki A. Right- and left-sided colon cancer - clinical and pathological differences of the disease entity in one organ. Arch Med Sci. 2017;13(1):157-162. [DOI:10.5114/aoms.2016.58596] [PMID] [PMCID]
11. Sun M, Xia R, Jin F, Xu T, Liu Z, De W, Liu X. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol. 2014;35(2):1065-73. [DOI:10.1007/s13277-013-1142-z] [PMID]
12. Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, et al. MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures. Nat Commun. 2019; 21;10(1):5290. [DOI:10.1038/s41467-019-13200-7] [PMID] [PMCID]
13. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, et al. Activation of p53 by MEG3 non-coding RNA. J Biol Chem. 2007;282(34):24731-42. [DOI:10.1074/jbc.M702029200] [PMID]
14. Kruer TL, Dougherty SM, Reynolds L, Long E, de Silva T, Lockwood WW, Clem BF. Expression of the lncRNA Maternally Expressed Gene 3 (MEG3) Contributes to the Control of Lung Cancer Cell Proliferation by the Rb Pathway. PLoS One. 2016;11(11):e0166363. [DOI:10.1371/journal.pone.0166363] [PMID] [PMCID]
15. Shaker O, Ayeldeen G, Abdelhamid A. The Impact of Single Nucleotide Polymorphism in the Long Non-coding MEG3 Gene on MicroRNA-182 and MicroRNA-29 Expression Levels in the Development of Breast Cancer in Egyptian Women. Front Genet. 2021;12:683809. [DOI:10.3389/fgene.2021.683809] [PMID] [PMCID]
16. Ali MA, Shaker OG, Alazrak M, AbdelHafez MN, Khalefa AA, et al. Association analyses of a genetic variant in long non-coding RNA MEG3 with breast cancer susceptibility and serum MEG3 expression level in the Egyptian population. Cancer Biomark. 2020;28(1):49-63. [DOI:10.3233/CBM-191072] [PMID]
17. Liu H, Ye D, Chen A, Tan D, Zhang W, Jiang W, et al. A pilot study of new promising non-coding RNA diagnostic biomarkers for early-stage colorectal cancers. Clin Chem Lab Med. 2019;57(7):1073-1083. [DOI:10.1515/cclm-2019-0052] [PMID]
18. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8. [DOI:10.1038/nprot.2008.73] [PMID]
19. Zhang J, Lin Z, Gao Y, Yao T. Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. J Exp Clin Cancer Res. 2017;36(1):5.
https://doi.org/10.1186/s13046-016-0472-2 [DOI:10.1186/s13046-015-0120-2] [PMID] [PMCID]
20. Modali SD, Parekh VI, Kebebew E, Agarwal SK. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol. 2015;29(2):224-37. [DOI:10.1210/me.2014-1304] [PMID] [PMCID]
21. Sabarinathan R, Tafer H, Seemann SE, Hofacker IL, Stadler PF, Gorodkin J. The RNAsnp web server: predicting SNP effects on local RNA secondary structure. Nucleic Acids Res. 2013;41(Web Server issue):W475-9. [DOI:10.1093/nar/gkt291] [PMID] [PMCID]
22. Han X, Zheng Z, Wang C, Wang L. Association between MEG3/miR-181b polymorphisms and risk of ischemic stroke. Lipids Health Dis. 2018 Dec 22;17(1):292. [DOI:10.1186/s12944-018-0941-z] [PMID] [PMCID]
23. Ghaedi H, Zare A, Omrani MD, Doustimotlagh AH, Meshkani R, Alipoor S, Alipoor B. Genetic variants in long noncoding RNA H19 and MEG3 confer risk of type 2 diabetes in an Iranian population. Gene. 2018;675:265-271. [DOI:10.1016/j.gene.2018.07.002] [PMID]
24. Han D, Wang M, Ma N, Xu Y, Jiang Y, Gao X. Long noncoding RNAs: novel players in colorectal cancer. Cancer Lett. 2015;361(1):13-21. [DOI:10.1016/j.canlet.2015.03.002] [PMID]
25. Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, et al. Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes Cancer. 2011;2(8):829-40. [DOI:10.1177/1947601911431081] [PMID] [PMCID]
26. Svoboda M, Slyskova J, Schneiderova M, Makovicky P, Bielik L, Levy M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014;35(7):1510-5. [DOI:10.1093/carcin/bgu055] [PMID]
27. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012;48(3):R45-53. [DOI:10.1530/JME-12-0008] [PMID] [PMCID]
28. Ghafouri-Fard S, Taheri M. Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA. Biomed Pharmacother. 2019;118:109129. [DOI:10.1016/j.biopha.2019.109129] [PMID]
29. Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res. 2010;70(6):2350-8. [DOI:10.1158/0008-5472.CAN-09-3885] [PMID] [PMCID]
30. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab. 2005;90(4):2179-86. [DOI:10.1210/jc.2004-1848] [PMID]
31. Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC, Maher ER. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer. 2005;92(8):1574-80. [DOI:10.1038/sj.bjc.6602478] [PMID] [PMCID]
32. Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an Oncogenic Long Non-coding RNA in Different Cancers. Pathol Oncol Res. 2019;25(3):859-874. [DOI:10.1007/s12253-019-00614-3] [PMID]
33. Cao X, Zhuang S, Hu Y, Xi L, Deng L, et al. Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese. Oncotarget. 2016;7(14):19054-9. [DOI:10.18632/oncotarget.7764] [PMID] [PMCID]
34. Hou Y, Zhang B, Miao L, Ji Y, Yu Y, Zhu L, et al. Association of long non-coding RNA MEG3 polymorphisms with oral squamous cell carcinoma risk. Oral Dis. 2019;25(5):1318-1324. [DOI:10.1111/odi.13103] [PMID]
35. Xu B, Zhang M, Liu C, Wang C, You Z, Wang Y, Chen M. Association of Long Non-Coding RNA MEG3 Polymorphisms and Risk of Prostate Cancer in Chinese Han Population. Urol J. 2020;18(2):176-180.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
